HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Get Rating) in a research note released on Monday morning, Benzinga reports. The firm currently has a $4.00 target price on the stock. SAB Biotherapeutics Price Performance SAB Biotherapeutics stock opened at $0.44 on Monday. The stock’s 50 day moving average price […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $4.00 target price on the stock. SAB Biotherapeutics Trading Up 4.1 % Shares of SABS stock opened at $0.48 on Monday. The […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Sutro Biopharma (NASDAQ:STRO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Analyst Ratings This is a breakdown of current ratings […]
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Rating) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 8,100 shares, a decrease of 64.9% from the February 28th total of 23,100 shares. Based on an average daily trading volume, of 5,400 shares, the short-interest ratio […]
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Rating) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 8,100 shares, a drop of 64.9% from the February 28th total of 23,100 shares. Based on an average trading volume of 5,400 shares, the days-to-cover ratio is […]